Papaverine safety during pregnancy: Insights from a large population‐based cohort of pregnancies
Exposure to papaverine during pregnancy was not associated with adverse pregnancy outcomes in the population studied, compared with non-exposed pregnancies.
Authors
- Yael Levi
- Tal Michael (ORCID: https://orcid.org/0000-0002-0328-055X)
- Sharon Daniel (ORCID: https://orcid.org/0000-0003-1820-9278)
- Eitan Lunenfeld (ORCID: https://orcid.org/0000-0003-2260-9530)
- Amalia Levy (ORCID: https://orcid.org/0000-0002-2355-8854)
- Gali Pariente (ORCID: https://orcid.org/0000-0001-6484-3769)
- Saar Dor
- Shira Birenstock‐Choen
Institutions
- Ben-Gurion University of the Negev (IL)
- Soroka Medical Center (IL)
- Ariel University (IL)
- Clalit Health Services (IL)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1111/bcp.16404
- Citations
- 1
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 1.88